Evidence map›Paper›PMID 35280104›Full record

ArticleClinical case reports2022

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report.

Morten Bahrt Haulrig, Signe Ledou Nielsen, Jesper Elberling, Lone Skov

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Erratum:.Clinical case reports · 2022
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Morten Bahrt HaulrigDepartment of Dermatology and Allergy Herlev and Gentofte Hospital University of Copenhagen Hellerup Denmark.ORCID https://orcid.org/0000-0002-5553-3213
Signe Ledou NielsenDepartment of Pathology, Herlev and Gentofte Hospital University of Copenhagen Herlev Denmark.
Jesper ElberlingDepartment of Dermatology and Allergy Herlev and Gentofte Hospital University of Copenhagen Hellerup Denmark.
Lone SkovDepartment of Dermatology and Allergy Herlev and Gentofte Hospital University of Copenhagen Hellerup Denmark.
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70-year-old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her lesions after three months.

Indexed as

linear IgA bullous dermatosislinear IgA/IgG bullous dermatosisomalizumabxolair

Identifiers

PMID35280104
PMCPMC8905130
OpenAlexW4220710727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.